Although elderly patients (≥70 years) represent 30% of new diagnoses of soft tissue sarcoma (STS), they are underrepresented in clinical trials and are often unfit to receive standard anthracycline-based chemotherapy. Trabectedin is registered as a second-line treatment for advanced STS and is characterized by a favorable safety profile.
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group
Grosso, Federica;D'Ambrosio, Lorenzo;Matteo, Cristina;D'Incalci, Maurizio;
2020-01-01
Abstract
Although elderly patients (≥70 years) represent 30% of new diagnoses of soft tissue sarcoma (STS), they are underrepresented in clinical trials and are often unfit to receive standard anthracycline-based chemotherapy. Trabectedin is registered as a second-line treatment for advanced STS and is characterized by a favorable safety profile.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Cancer - 2020 - Grosso et al.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
332.56 kB
Formato
Adobe PDF
|
332.56 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
